Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity

Acta Ophthalmol. 2014 Sep;92(6):e496-7. doi: 10.1111/aos.12339. Epub 2014 Jan 16.

Authors

Sarah Moran¹, Michael O'Keefe, Claire Hartnett, Bernadette Lanigan, John Murphy, Veronica Donoghue

Affiliation

¹ Department of Ophthalmology, Children's University Hospital, Dublin 1, Ireland.

PMID: 24428792
DOI: 10.1111/aos.12339

No abstract available

Publication types

Comparative Study
Letter
Randomized Controlled Trial

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Bevacizumab
Case-Control Studies
Electroretinography
Evoked Potentials, Visual
Humans
Infant
Infant, Newborn
Intravitreal Injections
Laser Coagulation / methods*
Lasers, Semiconductor*
Magnetic Resonance Imaging
Prospective Studies
Recurrence
Retinopathy of Prematurity / classification
Retinopathy of Prematurity / drug therapy
Retinopathy of Prematurity / surgery
Retinopathy of Prematurity / therapy*
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
VEGFA protein, human
Vascular Endothelial Growth Factor A
Bevacizumab